words lines 0 60 0 20 top 50% bottom top 1 0 0 .22 back 1 0 .001 1 .1 1.5 none top bottom center center true 1 none top top center top true 0 200 .001 none
top bottom top center true 1 none top bottom bottom bottom true 1 none

Innovative Medicine Made Accessible to Those in Need

Our Story

Latest News

Pharmaceutical Company of the Year
Juniper Biologics Named “Pharmaceutical Company of the Year” at Corporate LiveWire Global Awards USA – English 
APAC Insider
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider
M&A Awards 2023
Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023
Latest COVID-19 Acquisition
Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore
GHP Most Innovative Oncology Pharmaceutical Company 2023
Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards
Caris
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
AIawar
Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022
Juniper_Announcement_Changes
Juniper Biologics Establishes Global Headquarters in Singapore 
Juniper & HELSINN
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
TGCnews2
Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis
Juniper Biologics Healthcare Therapy Oncology Rare Orphan Diseases Gene Therapy Grandma
Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)